Article information
Abstract
In 2008 isolates of KPC-producing Klebsiella pneumoniae (KPC-KPN) were detected for the first time at Hospital Heliópolis, São Paulo, Brazil. The aim of this study was to characterize the clinical and microbiological outcomes of infections caused by KPC-KPN. A historical cohort of patients from whom KPC-KPN strains were isolated was performed. Isolates were identified as resistant to ertapenem by automated broth microdilution system and screened as carbapenemase producers by the modified Hodge test. The beta-lactamase resistance gene blaKPC was detected by PCR. The genetic relatedness of isolates was determined by PFGE. The study provides early clinical experience in treating KPC-KPN infections in a Brazilian tertiary center.
Keyword:
Klebsiella pneumonia
KPC
hospital infection
carbapenemase
Full text is only aviable in PDF
References
[1.]
D.L. Paterson, R.A. Bonomo.
Extended-Spectrum β-Lactamases: a Clinical Update.
Clinical Microbiology Reviews, 18 (2005), pp. 657-686
[2.]
P. Nordmann, G. Cuzon, T. Naas.
The real threat of Klebsiella pneumoniae carbapenemase producing bacteria.
Lancet Infect Dis, 9 (2009), pp. 228-236
[3.]
C.A. Arias, B.M. Murray.
Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge.
N Engl J Med, 360 (2009), pp. 439-443
[4.]
H. Yigit, A.M. Queenan, G.J. Anderson, et al.
Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenemresistant strain of Klebsiella pneumoniae.
Antimicrob Agents Chemother, 45 (2001), pp. 1151-1161
[5.]
S. Bratu, S. Brooks, S. Burney, et al.
Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn.
New York. Clin Infect Dis, 44 (2007), pp. 972-975
[6.]
A. Leavitt, S. Navon-Venezia, I. Chmelnitsky, et al.
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
Antimicrob. Agents Chemother, 51 (2007), pp. 3026-3029
[7.]
Z.Q. Wei, X.X. Du, Y.S. Yu, et al.
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
Antimicrob Agents Chemother, 51 (2007), pp. 763-765
[8.]
G. Cuzon, T. Naas, M.C. Demachy, et al.
Plasmid-mediated carbapenem- hydrolyzing β-lactamase KPC in Klebsiella pneumoniae isolate from Greece.
Antimicrob Agents Chemother, 52 (2008), pp. 796-797
[9.]
M.V. Villegas, K. Lolans, A. Correa, et al.
First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America.
Antimicrob Agents Chemother, 50 (2006), pp. 2880-2882
[10.]
J. Monteiro, A.F. Santos, M.D. Asensi, et al.
First report of KPC- 2-producing-Klebsiella pneumoniae in Brazil.
Antimicrob Agents Chemother, 53 (2008), pp. 333-334
[11.]
G. Peirano, L.M. Seki, V.L. Val Passos, et al.
Carbapenem hydrolysing β-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil.
J Antimicrob Chemother, 63 (2009), pp. 265-268
[12.]
M. Pavez, P. Neves, M. Dropa, et al.
Emergence of carbapenemresistant Escherichia coli producing CMY-2-type AmpC betalactamase in Brazil.
J Med Microbiol, 57 (2008), pp. 1590-1592
[13.]
R.A. Garibaldi, J.P. Burke, M.L. Dickman, C.B. Smith.
Factors predisposing to bacteriuria during indwelling urethral catheterisation.
The New England Journal of Medicine, 291 (1974), pp. 213-219
[14.]
G. Stephen, Jenkins, P. David.
Calfee, Outcomes of Carbapenem- Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies.
Infect Control Hosp Epidemiol, 29 (2008), pp. 1099-1106
[15.]
S.A. Weisenberga, D.J. Morganc, R. Espinal-Witterb, D.H. Laroneb.
Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem.
Diagnostic Microbiology and Infectious Disease, 64 (2009), pp. 233-323
[16.]
D. Landman, C. Georgescu, D.A. Martin, J. Quale.
Polymyxins Revisited.
Clinical Microbiology Reviews, 21 (2008), pp. 449-465
[17.]
P. Hawkey, R. Finch.
Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Clin Microbiol Infect, 13 (2007), pp. 354-362
[18.]
M. Castanheira, H.S. Sader, L.M. Deshpande, T.R. Fritsche, R.N. Jones.
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing enterobacteriaceae: Report from the SENTRY antimicrobial surveillance program.
Antimicrobial Agents and Chemotherapy, 52 (2008), pp. 570-573
[19.]
K.B. Anthony, N.O. Fishman, D.R. Linkin, L.B. Gasink, P.H. Edelstein, E. Lautenbach.
Clinical and Microbiological Outcomes of Serious Infections with Multidrug- Resistant Gram-Negative Organisms Treated with Tigecycline.
Clinical Infectious Diseases, 46 (2008), pp. 567-570
[20.]
A.M. Nicasio, J.L. Crandon, D.P. Nicolau.
In vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates.
Antimicrobial Agents and Chemotherapy, 53 (2009), pp. 2756-2761
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
